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ARTICLE
Histone demethylase JMJD1C is phosphorylated
by mTOR to activate de novo lipogenesis
Jose A. Viscarra1,3, Yuhui Wang1,3, Hai P. Nguyen1, Yoon Gi Choi2 & Hei Sook Sul1*
Fatty acid and triglyceride synthesis increases greatly in response to feeding and insulin.
This lipogenic induction involves coordinate transcriptional activation of various enzymes in
lipogenic pathway, including fatty acid synthase and glycerol-3-phosphate acyltransferase.
Here, we show that JMJD1C is a specific histone demethylase for lipogenic gene transcription
in liver. In response to feeding/insulin, JMJD1C is phosphorylated at T505 by mTOR complex
to allow direct interaction with USF-1 for recruitment to lipogenic promoter regions. Thus, by
demethylating H3K9me2, JMJD1C alters chromatin accessibility to allow transcription.
Consequently, JMJD1C promotes lipogenesis in vivo to increase hepatic and plasma trigly-
ceride levels, showing its role in metabolic adaption for activation of the lipogenic program in
response to feeding/insulin, and its contribution to development of hepatosteatosis resulting
in insulin resistance.
https://doi.org/10.1038/s41467-020-14617-1 OPEN
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Hepatosteatosis is a major metabolic disorder correlatedwith obesity and insulin resistance (IR). However, therelationship between them is still controversial: obesity
and IR may cause hepatosteatosis, but whether hepatosteatosis
drives the obesity-associated IR is not known1. Hepatosteatosis
develops from a higher TG input than output and thus is influ-
enced by de novo lipogenesis (DNL)2. DNL is attenuated during
fasting, and increases drastically during feeding, with elevated
circulating insulin and glucose2. Improved understanding of the
regulation of lipogenesis may provide future therapeutic targets
for the ever-increasing metabolic diseases linked to accumulation
of excess fat.
Enzymes involved in lipogenesis, including fatty acid synthase
(FAS), and mGPAT, are regulated coordinately at the transcrip-
tional level3,4. Transcription factors (TF), including USF-1,
ChREBP, LXR, and SREBP-1c, play critical roles in this process.
USF-1 functions as a molecular switch by recruiting proteins to
the lipogenic promoters5. In response to insulin, USF-1 interacts
with DNA-PK and P/CAF for its phosphorylation and acetyla-
tion, respectively6. Phosphorylated and acetylated USF-1 then
recruits SREBP-1c to bind its nearby site, and interacts and
recruits BAF60c to bridge other BAF subunits to form LipoBAF
complex at lipogenic genes for chromatin remodeling7. In
addition, we found that a Mediator component, MED17 is
phosphorylated by CK2 to be recruited by USF-1, thus linking
USF-1 to the preinitiation complex formation for transcription8.
Importantly, this common mechanism governs transcription of
not only FAS but a battery of other lipogenic genes to fine-tune
the rate of lipogenesis4,9–11.
Epigenetic factors, such as histone modifiers, have been impli-
cated in the development of metabolic disorders, such as hepa-
tosteatosis and IR12. In adapting to environmental conditions,
dynamic histone marks may affect gene transcription in a site- and
tissue-specific fashion13. Although the best-studied histone mod-
ification so far is acetylation, histone methylation is an important
modification in epigenetic regulation of gene expression and cell
signaling13,14. The most common amino acid residue that can be
methylated is lysine and its ε-amine group can undergo mono-,
di- and trimethylation. For example, H3K4me3 is a well-accepted
activating mark, whereas H3K9me3 represents a repressive
mark13. There are many histone methyltransferases (HMT) and
demethylases (HDM) that act on histones. These enzymes require
co-factors or co-substrates. For example, JumonjiC domain-
containing HDMs are 2-oxoglutarate-dependent oxygenases15.
Thus, activities of histone modifiers are affected by intracellular
metabolites and metabolic state of the cells16. It also is plausible
that the histone modifiers may undergo posttranslational mod-
ification due to environmental cues, such as hormones and
nutrients. However, the molecular details underlying the specifi-
city of histone modifiers that function in specific processes or
potential regulation of these enzymes by posttranslational mod-
ification have not been well studied.
Here, we identify JMJD1C of Jumonji family as a critical epi-
genetic factor for lipogenesis. We show that, by direct interaction
with USF-1, JMJD1C is recruited to lipogenic promoters. We also
show that JMJD1C is phosphorylated at T505 by mammalian
target of rapamyci (mTOR) to be recruited to lipogenic genes in
response to insulin/feeding. By ATAC-seq, chromatin immuno-
precipitation sequencing (ChIP-seq) and RNA-seq, we show that
JMJD1C is specific for lipogenesis by demethylating H3K9
altering the chromatin accessibility. JMJD1C has been identified
in GWAS to be a candidate for aberrant serum triglyceride levels
and type 2 diabetes17–21. Overall, JMJD1C plays a central epige-
netic regulatory role for lipogenesis in response to insulin/feeding
and its dysregulation contributes to development of hepatostea-
tosis and associated IR.
Results
USF-1 recruits JMJD1C to lipogenic promoters. USF-1 is a
central player as a molecular switch for lipogenesis during fasting/
feeding by recruiting distinct TFs and signaling molecules6,7. To
identify epigenetic factors that are recruited by USF-1, we per-
formed tandem affinity purification (TAP) using USF-1 as bait,
followed by mass spectrometric analysis (MS) (Supplementary
Table 1). We identified JMJD1C, a member of JmjC-domain-
containing HDMs, as a USF-1 interacting protein. The function
of JMJD1C is not well studied but is reported to demethylate
H3K9me2/me122. By co-immunoprecipitation (co-IP), we
verified the USF-1- JMJD1C interaction after transfection of
Flag-tagged JMJD1C and HA-tagged USF-1into HEK293 cells
(Fig. 1a). We next performed GST-pull-down using purified GST-
USF-1 expressed in E. coli and pulled down in vitro translated
JMJD1C, demonstrating the direct interaction. We also tested
other TFs that are known to regulate lipogenesis, SREBP-1c, LXR,
and ChREBP. None of these TFs directly interacted with JMJD1C,
although SREBP-1c and LXR could make a complex with
JMJD1C indirectly (Supplementary Fig. 1a, b). Overall, these
results demonstrate the direct interaction of JMJD1C specifically
with USF-1 for lipogenic gene transcription.
We next examined domains of JMJD1C and USF-1 for
their interaction (Fig. 1b, left). Deletion of C-terminal basic
Helix-Loop-Helix (bHLH) of USF-1 prevented the interaction
with JMJD1C, indicating requirement of USF-1 bHLH domain
for JMJD1C interaction (Fig. 1b, right). (Fig. 1c, left). Conversely,
Co-IP clearly detected the USF-1 interaction with N-terminal
quarter of JMJD1C (JMJD1C (1-619)), but not the other three
regions of JMJD1C (Fig. 1c). We conclude that the bHLH domain
of USF-1 directly interacts with N-terminal region of JMJD1C
from aa 1 to 619.
We next tested the functional significance of the interaction
between USF-1 and JMJD1C. Co-transfection of USF-1 with the
−444-FAS promoter-luciferase construct increased luciferase
activity by approximately sixfold. While transfection of JMJD1C
alone did not have a significant effect, co-transfection of JMJD1C
along with USF-1 resulted in an ~27-fold increase in FAS
promoter activity (Fig. 1d, left and middle), demonstrating the
synergistic activation of FAS promoter by USF-1 and JMJD1C.
Treatment with Methylstat, an inhibitor of JmjC domain-
containing demethylases, prevented activation of the FAS
promoter, demonstrating the requirement of its demethylase
activity (Fig. 1d, middle). Using the various JMJD1C domains we
found that none of the four constructs, including the N-terminal
JMJD1C (1–619) or the Jumonji catalytic domain could increase
FAS-luciferase activity (Fig. 1d, right), suggesting that individu-
ally neither the USF-1 interacting N-terminal JMJD1C domain
nor the JmjC domain are sufficient for FAS promoter activation.
Next, by chromatin immunoprecipitation (ChIP), we tested
whether JMJD1C is recruited to the FAS promoter through
USF-1. We detected JMJD1C bound to the FAS promoter region
in insulin-treated HepG2 cells, but not in non-treated cells.
JMJD1C was also enriched approximately five- to sixfold in the
promoter regions of other lipogenic genes, such as ACC1 and
SREBF1 (Fig. 1e, left). We detected Jmjd1c bound to the Fas
promoter exclusively in the fed state (Fig. 1e, right). Jmjd1c was
enriched also at Acc1 and Srebf1 promoters only in the fed state
(Fig. 1e, right). In contrast, Jmjd1c was not detected in oxidative
genes, such as Acox1. These results show that JMJD1C is recruited
specifically to the lipogenic promoters in fed/insulin-treated
conditions.
JMJD1C activates lipogenic gene transcription in HepG2 cells.
Since JMJD1C is recruited specifically to activate lipogenic
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Fig. 1 JMJD1C interaction with USF-1 for FAS promoter activation. a IB of cell lysates of HEK293 cells co-transfected Flag-JMJD1C and HA-USF-1 with
Flag antibody after IP with HA antibody (left). Immunoblotting of liver lysates from fasted and fed mice after IP with JMJD1C antibody (top right) and USF-1
antibody (bottom right). b Diagram of GST-USF-1 constructs (left). Coomassie Blue staining of SDS-PAGE of purified GST-USF-1 protein from bacterial
lysates (middle). In vitro transcribed and translated S35-methioine labeled JMJD1C was incubated with GST-USF-1 and subjected them to SDS-PAGE,
followed by autoradiography (right). c Diagram of JMJD1C constructs (left). Co-IP of 293FT cells overexpressing Flag-tagged JMJD1C and USF-1.
Immunoblotting with anti JMJD1C antibody after IP with USF-1 antibody (right). d FAS promoter activity in 293FT cells that we co-transfected with USF-1
with or without JMJD1C (left), with or without 10 µM Methylstat (Sigma), JMJD1C inhibitor (middle), and after overexpression of various deletions of
JMJD1C (left). n= 10 wells of cells per group. Experiment was repeated three times. e ChIP for FAS, ACC, and SREBPF1 promoters in HepG2 cells with or
without insulin treatment (left, n= 4 per group) and ChIP for Fas, Acc1, and Srebf1 promoters in liver from fasted or fed mice (right, n= 3 per group) after
IP with JMJD1C antibody. Data are expressed as means ± SEM. **P < 0.01, ***P < 0.001, determined by two-tailed t-test. Source data are provided as a
source data file.
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promoters, we examined lipogenic gene expression in response
to insulin treatment by JMJD1C gain- and loss-of function.
Adenoviral transduction of JMJD1C resulted in fourfold higher
JMJD1C protein levels (Fig. 2a, left). This overexpression of
JMJD1C did not affect lipogenic gene expression in HepG2 cells
in the absence of insulin. FAS, ACC, GPAM, and SREBF1
messenger RNA (mRNA) levels were increased from four- to
sevenfold upon insulin treatment in JMJD1C overexpressing cells,
which were significantly higher than in control HepG2 cells that
showed only two to threefold increase (Fig. 2a, middle). Similar
changes in nascent RNA levels of these lipogenic genes were
detected also (Fig. 2a, right). In contrast, mRNA and nascent
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RNA levels of oxidative gene, ACOX, remained the same. We
conclude that JMJD1C promotes lipogenic gene transcription in
the presence of insulin. We next performed JMJD1C knockdown
(KD) in HepG2 cells to test the requirement of JMJD1C for
lipogenic gene activation in response to insulin. sh-JMJD1C
adenoviral transduction led to a 50% decrease in JMJD1C protein
levels (Fig. 2b, left). JMJD1C KD in the absence of insulin did not
have any effect on lipogenic gene expression(Fig. 2b, middle).
Moreover, expression levels remained low even in the presence of
insulin in JMJD1C KD cells, while they were ~2.5- to 3.5-fold
higher in control HepG2 cells in the presence of insulin (Fig. 2b,
middle), demonstrating the requirement of JMJD1C for lipogenic
gene activation in response to insulin. Treatment with Methylstat
had a similar effect and prevented induction of lipogenic genes,
even in insulin-treated cells (Fig. 2b, right).
JMJD1C activates lipogenesis in response to feeding in mice.
Next, we examined in vivo significance of Jmjd1c in hepatic
lipogenic gene activation. Administration of Jmjd1c adenovirus
caused Jmjd1c mRNA levels to increase sixfold compared to the
endogenous Jmjd1c levels in livers of mice (Fig. 2c, left). Upon
feeding, Fas mRNA levels were increased sevenfold by JMJD1C
overexpression. Similarly, other lipogenic genes, Acc, Srebf1, and
Scd1, were also higher (Fig. 2c, middle). Protein levels of Fas and
Srebp-1c were higher also (Fig. 2c, right). Hepatic DNL, deter-
mined by using heavy water-labeling followed by MS23, increased
~1.5-fold upon Jmjd1c overexpression (Fig. 2d). Oil Red O
(ORO) staining of liver sections showed higher lipid accumula-
tion in Jmjd1c overexpressing livers (Fig. 2e, left). Liver TG
content was also higher (Fig. 2e, right). We next administered
Jmjd1c shRNA adenovirus, which decreased the Jmjd1c protein
and mRNA levels livers by 60% (Fig. 2f, left). Hepatic mRNA
levels of lipogenic genes, including Fas, Gpam, and Acc1, were
significantly lower upon JMJD1C KD, while oxidative genes, such
as Acox1 and Acaa, did not change significantly (Fig. 2f, right).
We detected DNL to decrease by 30% in Jmjd1c KD livers
(Fig. 2g). Jmjd1c KD mice also had lower lipid staining in liver
(Fig. 2h, left) and hepatic triglyceride levels showed a 25%
decrease (Fig. 2h, right). These in vivo gain- and loss-of-function
experiments demonstrate that Jmjd1c promotes lipogenic gene
transcription and lipogenesis.
JMJD1C ablation blunts hepatic lipogenesis in mice. Jmjd1c is
widely expressed and global JMJD1C KO mice are infertile23.
To assess the liver-specific function of Jmjd1c, we generated liver-
specific Jmjd1c knockout mice (designated JMJD1C-LKO) by
crossing C57BL/6 JMJD1C-floxed mice with albumin-Cre mice
(Fig. 3a, left). Jmjd1c mRNA level in livers of JMJD1C-LKO mice
was decreased by 70%, but not in other tissues (Fig. 3a, middle).
Jmjd1c protein was non-detectable in livers of JMJD1C-LKO
mice (Fig. 3a, right). mRNA levels for lipogenic genes, including
Fas, Gpam, Acc1, and Scd1 in livers of JMJD1C-LKO mice on
chow diet, were ~50% lower compared to WT littermates (Fig. 3b,
left). Fas and Srebp-1c protein levels were lower also (Fig. 3b,
middle). We subjected JMJD1C-LKO mice to fasting/feeding
cycle. Nascent RNA levels of lipogenic genes were drastically
increased upon 6 h refeeding of high-carbohydrate (CHO) diet
compared to fasting in WT mice. However, nascent RNA levels
remained low in livers of JMJD1C-LKO mice even after feeding
(Fig. 3b, right). ORO staining of livers showed lower lipid accu-
mulation in fed JMJD1C-LKO mice (Fig. 3c, left). Liver TG
content also was lower (Fig. 3c, right). Serum TG but not serum
FFA levels were lower in JMJD1C-LKO mice than WT mice
(Fig. 3d). Glycogen staining showed greater accumulation of
glycogen in liver but not in muscle of JMJD1C-LKO mice (Fig. 3e
and Supplementary Fig. 2D) These data support the concept that
JMJD1C is required for induction of lipogenesis in livers of mice
in response to feeding.
Next, we subjected JMJD1C-LKO mice to a high-CHO diet, a
standard regimen for promotion of DNL. Similar to those on
chow diet, mRNA and nascent RNA levels of lipogenic genes in
livers of JMJD1C-LKO mice on high-CHO diet were significantly
lower than in WT littermates (Fig. 3f). DNL rate was 33% lower
in livers of JMJD1C-LKO mice (Fig. 3g). Liver TG levels also were
lower in JMDJ1C-LKO mice (Fig. 3h–i), although liver TG levels
in both WT and KO mice were higher than on chow diet
(Supplementary Fig. 2c), demonstrating that Jmjd1c ablation
protected mice from hepatosteatosis from high-CHO diet regi-
men. Serum TG levels of JMJD1C-LKO mice compared to WT
littermates were lower (Fig. 3j). In contrast, glycogen levels upon
refeeding were higher in the JMJD1C-LKO livers (Fig. 3k).
Neither WT nor JMJD1C-LKO mice on high-CHO diet had
higher white adipose tissue (WAT) mass or adiposity compared
to chow fed mice (Fig. 3l). However, GTT and ITT showed IR in
WT mice. In contrast, GTT and ITT showed significantly lower
glucose levels in JMJD1C-LKO mice, compared to the WT
(Fig. 3m) and were similar to when on chow diet (Supplementary
Fig. 2a, b), demonstrating that Jmjd1c ablation prevented glucose
intolerance and IR from high-CHO feeding.
We also examined the potential involvement of Jmjd1c in
lipogenic gene activation by Srebp-1c and Lxr24,25. We over-
expressed Srebp-1c by adenoviral transduction or administered
Lxr agonist, T0901317. As expected, WT mice showed a 2–3-fold
increase in lipogenic gene expression by either of these treatments
(Supplementary Fig. 3b, c). This lipogenic gene induction was
partially blunted in JMJD1C-LKO mice, demonstrating involve-
ment of Jmjd1c in Srebp-1c and Lxr function, probably via their
indirect interaction (Supplementary Fig. 1) and/or these TFs may
require chromatin accessibility brought by Jmjd1c at the lipogenic
promoters (see below).
We next subjected JMJD1C-LKO mice to high-fat diet (HFD)
to test whether Jmjd1c affects diet-induced obesity. Both WT and
JMJD1C-LKO mice on HFD showed a typical obesity phenotype
Fig. 2 JMJD1C promotes lipogenesis. a Immunoblotting of lysates from HepG2 cells infected with JMJD1C adenovirus (left). RT-qPCR for mRNA levels
(middle) and nascent RNA levels (right) of lipogenic genes in HepG2 cells with or without insulin treatment. n= 4 wells of cells per group. Experiment was
repeated three times. b Immunoblotting of lysates from HepG2 cells infected with sh-JMJD1C adenovirus (left). RT-qPCR for mRNA levels of lipogenic
genes (middle) and mRNA levels of lipogenic genes in HepG2 cells with or without 10 µM Methylstat treatment (right). n= 4 wells of cells per group.
c Immunoblotting for JMJD1C protein and RT-qPCR for mRNA levels (left) in livers of mice 10 days after tail-vein injection of 2 × 108 pfu JMJD1C
adenovirus in PBS (n= 5). Mice were fasted for 16 h and then refed with HCD for 8 h before tissue harvesting. mRNA levels of lipogenic genes (middle).
Immunoblotting of lysates from livers for Fas and Srebp-1c (right). d De novo lipogenesis, e Oil red O staining of liver tissue sections (left), and liver
triglyceride levels (right) n= 5 per group. f Jmjd1c protein and mRNA levels (left two) in livers of mice 10 days after tail-vein injection of sh-JMJD1C
adenovirus (n= 5). mRNA levels of lipogenic genes (right). g De novo lipogenesis, h Oil red O staining of liver tissue sections (left) and liver triglyceride
levels (right). Data are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, determined by two-tailed t-test. Scale bar= 100 μm. Source data are
provided as a source data file.
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with higher WAT mass (Supplementary Fig. 2e). WT mice
showed liver TG accumulation and development of glucose
intolerance (Supplementary Fig. 2f, h). In contrast, JMJD1C-LKO
mice on HFD remained insulin-sensitive, protected from diet-
induced obesity-related IR (Supplementary Fig. 2h), even when
these mice still manifested higher WAT mass. These results
demonstrate that Jmjd1c ablation can improve IR even in the
presence of obesity caused by HFD.
JMJD1C demethylates H3K9 at lipogenic promoters. Although
JMJD1C is reported to demethylate H3K922,26, little is known
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regarding the change in H3K9 methylation at lipogenic pro-
moters upon insulin/feeding. By ChIP–quantitative PCR (qPCR),
we detected ~60% lower H3K9me3 enrichment at the promoters
of lipogenic genes, such as FAS, ACC, and SREBF1, in insulin-
treated HepG2 cells (Fig. 4a, top). H3K9me2 enrichment was also
30–55% lower, while H3 level remained constant (Fig. 4a).
Conversely, H3K9me1 enrichment increased twofold upon
insulin treatment. We detected approximately sevenfold greater
enrichment of H3K4me3 upon insulin treatment (Fig. 4b).
Changes in H3K9 methylation were specific to lipogenic genes,
since we did not detect changes in promoter regions of oxidative
genes, such as ACOX. ChIP experiments using livers from fasted
and fed mice showed lower enrichment of H3K9me3 and
H3K9me2, and greater enrichment of H3K9me1 at lipogenic
promoters in livers of fed mice (Fig. 4a). Enrichment of
H3K4me3 was higher in refed mice (Fig. 4b).
We next performed in vitro demethylation assays using
individual H3K9me3, H3K9me2, or H3K9me1 peptides to test
JMDJ1C activity. We detected nearly complete demethylation of
the H3K9me2, ~50% demethylation of H3K9me1, and virtually
no demethylation of the H3K9me3 (Fig. 4c). To define the role of
JMJD1C in H3K9 demethylation in the activation of lipogenic
genes, we next compared H3K9 methylation status at the
lipogenic promoter regions in livers of JMJD1C-LKO and WT
mice. We detected greater enrichment of H3K9me3, H3K9me2,
and H3K9me1 at the lipogenic promoters, including Fas and
Gpam, but not in Acox1, in livers of JMJD1C-LKO, compared to
WT mice in the fed state (Fig. 4d, left and middle). (Fig. 4d,
right). Interestingly, though JMJD1C had no H3K9me3 demethy-
lase activity, we still detected accumulation of H3K9me3 in
JMJD1C-LKO mice. It is possible that a yet to be identified HMT
for H3K9 is not regulated by fasting/feeding and thus accumula-
tion of H3K9me2 caused H3K9me3 accumulation. Overall, our
results support the concept that JMJD1C demethylates H3K9me2
for activation of lipogenic genes upon feeding/insulin treatment.
Genome-wide analyses of JMJD1C function in livers of mice.
With the known function of JMJD1C as an H3K9 HDM, JMJD1C
is predicted to play a role in regulating the transcriptional land-
scape. We therefore assessed the chromatin landscape by Assay
for Transposase-Accessible Chromatin (ATAC-seq). ATAC-seq
showed concentrated open chromatin regions near the tran-
scription start sites (TSS), in both WT fasted and refed samples,
as well as refed JMJD1C-LKO (Fig. 5a). Approximately 38% of
peaks to be at the TSS, 25% in the intragenic regions, while 37%
were spread out throughout intergenic regions (Supplementary
Fig. 5a). Gene ontology identified lipogenesis exclusively in the
refed sample, while those genes involved in processes of gluco-
neogenesis appeared exclusively in fasted samples (Fig. 5b, top).
RNA processing and translation, along with various lipid bio-
synthetic processes were detected exclusively in WT, but not
JMJD1C-LKO (Fig. 5b, bottom). Genes involved in chromatin
organization such as Hdac, Arid, Jarid, Hmt, Set-domain con-
taining, and Smarca families that are known to alter chromatin
structure to repress transcription27–30, were detected in open
chromatin in both WT and JMJD1C-LKO (Fig. 5b, bottom).
Motif analysis detected 55 known transcription factor motifs that
were significantly enriched in the WT but not in the JMJD1C-
LKO (Supplementary Table 2). Interestingly the motif for Usf-1
was among these (Supplementary Table 2), suggesting that
Jmjd1c ablation impacted Usf-1 function other than in lipogenic
gene regulation. With our primary interest in assessing JMJD1C’s
role in the regulation of lipogenesis, we compared peaks for a
subset of lipid biosynthetic genes. Indeed, we found that lipogenic
promoters were more open upon feeding than fasting (Fig. 5c).
Conversely, promoter regions of gluconeogenic genes were more
open during fasting than refeeding, while the promoter region of
Jmjd1c was not different between fasting/feeding, consistent with
our finding that Jmjd1c expression was not regulated by fasting/
feeding (Fig. 5c and Supplementary Fig. 5). Comparing WT peaks
to that of the JMJD1C-LKO showed much smaller peaks and no
apparent change as a result of feeding (Fig. 5c) at lipogenic
promoters.
We performed ChIP-seq that detected greater enrichment of
H3K9me2 at the TSS in fasted and refed samples, however
H3K9me2 enrichment was detected also in the proximal
promoter regions, as well as within gene bodies (Fig. 5d).
Approximately 46% of peaks were found near the TSS, 50% were
found in intragenic regions, and 4% were found in intergenic
regions (Supplementary Fig. 5b). H3K9me2 enrichment upon
refeeding was detected at genes from processes known to be
suppressed, such as those for gluconeogenesis and MAPK
signaling (Fig. 5e, left). Similarly, H3K9me2 enrichment in fasted
livers was detected at those genes repressed during fasting, such as
those involved in lipogenesis, as well as insulin and TOR signaling
(Fig. 5e, left). Comparing ATAC-seq and H3K9me2 ChIP-seq of
refed livers, showed distinct gene profiles (Fig. 5e, right). Open
chromatin regions were found in lipogenic promoters and were
not enriched in H3K9me2, whereas gluconeogenic or fatty acid
oxidative genes were found to be H3K9me2 enriched, but not
detected among open chromatin regions in the refed livers.
Among the genes exclusive to either ATAC-seq or H3K9me2
ChIP-seq datasets, Chromatin Organization again was the most
enriched process. We then examined peaks for representative
lipogenic (Fas) and oxidative (Acot1) promoters and compared
them to those we detected in ATAC-seq. ATAC-seq showed
open chromatin regions for Fas only in the refed, while that of
Acot1 was only open in the fasted (Fig. 5f). However, H3K9me2
ChIP-seq from refed livers detected peaks for Acot1, but not for
Fas (Fig. 5f), showing repression of Acot1 but not Fas during
refeeding.
We next performed RNA-seq to determine the effect of Jmjd1c
depletion in the liver. Protein synthesis was detected to be the
most affected process downregulated in JMJD1C-LKO mice, with
various initiation/elongation factors, ribosomal proteins, and
transfer RNA (tRNA) synthetases being downregulated (Fig. 5g,
left). Chromatin modification, regulation of cell cycle, lipogenesis,
and DNA maintenance were also downregulated in JMJD1C-
Fig. 3 Lipogenesis is impaired in liver-specific JMJD1C knockout mice. a Schematics of conditional knockout allele of JMJD1C (left). RT-qPCR for Jmjd1c
mRNA levels in tissues, n= 5 mice (middle) and immunoblotting of liver tissue lysates with JMJD1C antibody (right). b RT-qPCR for mRNA (left),
immunoblotting of liver tissue lysates with Fas and Srebp-1c antibodies (middle), and nascent RNA (right). c Oil red O staining of liver tissue sections and
liver triglyceride level. d Serum triglyceride and FFA levels in 12-week-old mice on chow diet. e Periodic acid–Schiff (PAS) staining for glycogen of liver
tissues and glycogen levels in liver. a–e n= 8 mice per group. f–n JMJD1C-LKO mice and their WT littermates were fed a High CHO (70 kcal% carb) for
4 months after weaning, n= 6 mice per group. f mRNA (left) and nascent RNA (right), g de novo lipogenesis, h liver triglycerides, i Oil red O staining of
liver tissue sections, j serum triglyceride levels, k liver glycogen levels, l and tissue weights. m GTT and ITT for high-CHO diet, and n serum insulin level.
Data are expressed as means ± SEM. *P < 0.05, **P < 0.01, determined by two-tailed t-test. Scale bar= 100 μm. Source data are provided as a source
data file.
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LKO mice (Fig. 5g, left). Genes in various metabolic processes
were also detected to be upregulated in the JMJD1C-LKO mice
(Fig. 5g, left). The most significantly affected was glycolysis, with
phosphofructokinase, aldolase, and phosphoglycerate kinase,
among others, being upregulated in the JMJD1C-LKO livers.
We next compared genes downregulated in the JMJD1C-LKO
mice to those detected in refed WT mice by ATAC-seq. We
reasoned that if these genes were directly downregulated due to
depletion of Jmjd1c, they should coincide with genes detected in
the refed WT by ATAC-seq. We detected similar processes
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Fig. 4 Enrichment of H3K9me2 is decreased on lipogenic promoters by feeding/insulin. a ChIP for enrichment of H3K9me3, H3K9me2, and H3K9me1
on FAS, ACC, and SREBF1 promoters in HepG2 cells with or without insulin treatment (top) n= 4 wells of cells per group. ChIP for enrichment of H3K9me3,
H3K9me2, and H3K9me1 on lipogenic gene promoters in livers from fasted and fed mice (bottom) n= 4 per group. b ChIP for enrichment of H3K4me3 on
lipogenic promoters upon insulin/feeding, n= 4 per group. c In vitro demethylation assays using individual H3K9me3, H3K9me2, or H3K9me1 peptides,
along with control or JMJD1C expressing HepG2 cell lysates, n= 4 dishes of cells per group. d ChIP for enrichment of H3K9me3, H3K9me2, and H3K9me1
on Fas and Gpam promoters in livers from JMJD1C-LKO and their WT littermates on chow diet in the fed state. n= 8 per group. Data are expressed as
means ± SEM. *P < 0.05, **P < 0.01, determined by two-tailed t-test. Source data are provided as a source data file.
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Fig. 5 Genome-wide analyses of JMJD1C function in liver. a–c ATAC-seq using livers fromWT and JMJD1C-LKO mice that were fasted or refed. n= 2 per
group. a Heatmaps showing open chromatin regions focused at the transcription start site (TSS). Color scale shows peaks detected, black is equivalent to
zero, yellow is equivalent to 500. b Venn diagrams showing number of unique or shared genes and charts for representative top gene ontology (GO)
terms. c UCSC genome browser screenshot of representative peaks at a subset of promoter regions. d–f H3K9me2 ChIP-seq using livers from WT refed
mice, n= 2 per group. d Heatmap showing H3K9me2 enrichment at TSS (color scale shows peaks detected, black is equivalent to zero, yellow is equivalent
to 500) and e representative top GO terms for genes detected to be H3K9me2 enriched differentially upon fasting or refeeding. Venn diagrams showing
number of unique or shared genes between ATAC- and ChIP-seq datasets and charts for representative top gene ontology (GO) terms (right). f UCSC
genome browser screenshot of representative peaks at a subset of promoter regions. g RNA-seq using livers from refed WT and JMJD1C-LKO mice, n= 2
pooled RNA samples per group. Heatmap showing changes in gene expression between WT and JMJD1C-LKO mice (left), Color scale shows changes in
gene expression as determined by Z-score, green is –1.42 and red is 1.49. Representative top GO terms of upregulated and downregulated genes identified
by differential expression analysis (middle). Venn diagrams showing number of unique or shared genes between ATAC- and RNA-seq datasets and charts
for representative top gene ontology (GO) terms (right).
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between the two datasets, including protein synthesis, chromatin
modification, lipogenesis, and apoptosis (Fig. 5g, right). Genes
involved in protein synthesis detected in both datasets included
initiation/elongation factors, ribosomal proteins, and tRNA
synthetases. The chromatin modifying genes found in both
ATAC and RNA-seq datasets were composed of Arid, Jarid,
Hdac, and Smarca family members, which are known to function
primarily in transcriptional repression. From these comparisons,
it is clear that JMJD1C plays a critical role in the activation of
transcription of lipogenic genes. Moreover, JMJD1C also appears
to play an important role in regulating the expression of other
histone modifiers and chromatin remodelers.
JMJD1C is phosphorylated at T505 by mTOR. We next asked
how JMJD1C activates lipogenic gene transcription in response to
feeding/insulin treatment. JMJD1C mRNA and protein levels
remained the same in HepG2 cells, whether treated with insulin
or not (Fig. 6a, left), and in livers of fasted or fed mice (Fig. 6a,
right). Therefore, changes in JMJD1C levels cannot explain
JMJD1C-mediated action on lipogenesis in response to insulin/
feeding. Additionally, we did not detect any changes in nuclear
levels of JMJD1C, eliminating translocation as an underlying
mechanism. Since α-ketoglutarate (αKG) serves as an obligatory
co-factor for the Jumonji HDMs, we examined if αKG levels are
altered in response to insulin/feeding, and detected a threefold
increase in intracellular αKG in insulin-treated HepG2 cells
(Fig. 6b, left). Similarly, αKG levels were higher in livers of refed
mice (Fig. 6b, right). Moreover, treatment of HepG2 cells with a
cell-permeable analog of αKG, dimethyl-ketoglutarate (DMKG),
further increased FAS and other lipogenic gene expression in a
dose-dependent manner (Fig. 6c). We also examined H3K9
methylation status of lipogenic promoters by ChIP following
insulin/DMKG treatment. Insulin-treated cells had lower
enrichment of H3K9me3 and H3K9me2, and greater enrichment
of H3K9me1(Fig. 6d). Cells to which insulin and DMKG were
added had even lower enrichment of H3K9me2, and greater
accumulation of H3K9me1, at lipogenic promoters compared to
the insulin-treated cells (Fig. 6d).
To examine if changes in αKG levels can fully explain the
JMJD1C-mediated activation of lipogenic genes in response to
insulin/feeding treatment, we next assayed for the demethylase
activity of JMJD1C purified from HepG2 cells in the excess
presence of all of the required co-factors and substrates, including
αKG. Notably, we detected significantly higher demethylase
activity of JMJD1C purified from insulin-treated HepG2 cells
(Fig. 7a). Similarly, we detected higher demethylase activity with
the immuno-purified JMJD1C from livers of fed mice (Fig. 7a).
Higher demethylase activity of JMJD1C from insulin/feeding
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Fig. 6 α-KG level increases upon feeding/insulin treatment in liver for JMJD1C activity. a RT-qPCR for JMJD1C mRNA level and immunoblotting with
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treatment, suggests that JMJD1C could be posttranslationally
modified in response to insulin/feeding.
We next examined the possibility of posttranslational modifica-
tion of JMJD1C. Immunoblotting using pan-p-Ser antibody
detected signals in both insulin-treated and non-treated cells,
although the signal was somewhat stronger in insulin-treated cells
(Fig. 7b, left). In contrast, immunoblotting with pan-p-Thr
antibody showed phosphorylation only in insulin-treated cells,
but not in non-treated cells (Fig. 7b, left). We then subjected
immuno-purified JMJD1C, from insulin-treated, JMJD1C-HA
transduced HepG2 cells to MS analysis and identified four
phosphor-Ser-containing peptides with S188, S604, S607, and
S2053, as well as one phospho-Thr-containing peptide with T505
(Fig. 7b, right). We generated site-specific mutation constructs
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replacing Ser or Thr to non-phosphorylatable Ala mutants, as well
as phosphorylation-mimicking Asp mutants for S188, S604,
S2053, and T505 for FAS-Luc assay. None of the Ser mutants
changed the FAS promoter activity (Fig. 7c). However, the T505A
mutant showed 40% lower FAS promoter activity compared to the
WT JMJD1C (Fig. 7c). The phosphorylation-mimicking T505D
mutant showed higher FAS activity, although the magnitude of
increase was small, probably because the cells were maintained in
the presence of insulin causing phosphorylation of the WT
JMJD1C (Fig. 7c). These results support that JMJD1C T505
phosphorylation plays a key role in the activation of the FAS
promoter by JMJD1C. We then generated an antibody specific to
phosphorylated T505 (p-T505) to examine insulin/feeding-
induced phosphorylation of JMJD1C. Indeed, we detected
phosphorylation of T505 of the endogenous JMJD1C exclusively
in insulin-treated HepG2 cells and not in non-treated cells
(Fig. 7d, top). We also detected T505 phosphorylation of the
endogenous JMJD1C from livers of fed, but not fasted, mice
(Fig. 7d, bottom). A review of phospho-protein databases
predicted that mTOR could potentially phosphorylate the T505
of JMJD1C. By performing in vitro phosphorylation assay using
mTORC1 (including mTOR, RAPTOR, and Rheb), we detected
phosphorylation of T505 of JMJD1C (Fig. 7e, left). Furthermore,
we detected phosphorylation of WT JMJD1C but not T505A
mutant when we co-transfected JMJD1C constructs along with the
mTORC1 in 293FT cells (Fig. 7e, right). Moreover, rapamycin
treatment completely blocked phosphorylation of Jmjd1c at T505,
and decreased lipogenic gene expression by 60–70% (Fig. 7f).
Administration of adenoviral shRNA for Raptor blocked Jmjd1c
T505 phosphorylation (Fig. 7g) and lipogenic gene expression was
80% lower in Raptor KD livers. These results indicate that T505 of
JMJD1C is phosphorylated by mTORC1 upon insulin/feeding.
We next tested whether the JMJD1C interaction with USF-1 is
affected by JMJD1C phosphorylation. Indeed, Co-IP experiments
detected interaction of USF-1 with WT and the T505D mutant
but not with T505A mutant, showing that T505 phosphorylation
enhances interaction with USF-1 (Fig. 7h). Co-IP showed a strong
interaction between endogenous USF-1 and JMJD1C only in
livers from fed but not fasted mice (Fig. 7i). We also detected
an interaction between JMJD1C and LipoBAF complex
member BAF60c, which was exclusively detected in refed livers
(Supplementary Fig. 6). We next examined the effect of JMJD1C
phosphorylation on recruitment to the FAS promoter. (Fig. 7j).
By ChIP, we detected ~12-fold enrichment of WT JMJD1C at the
FAS promoter, and ~17-fold enrichment of the T505D JMJD1C
mutant. Enrichment of the T505A JMJD1C mutant was
considerably lower than both WT and T505D JMJD1C (Fig. 7j).
These results indicate that T505 phosphorylation enhances
JMJD1C-USF-1 interaction for recruitment to the FAS, and
likely other lipogenic promoters.
Finally, to evaluate the effect of JMJD1C T505 phosphorylation
in vivo, we injected control GFP, WT JMJD1C, or JMJD1C
T505D mutant to JMJD1C-LKO mice. Protein levels of various
JMJD1C forms were similar (Fig. 7k). Compared to WT control,
hepatic levels of lipogenic genes, including Fas, Acc1 and Srebf1,
were lower by 60–90% in JMJD1C-LKO mice (Fig. 7k, left).
Administration of WT JMJD1C restored the gene expression up
to 75–80% of WT levels. More importantly, administration of
JMJD1C containing T505D mutation increased lipogenic gene
expression 20-30% higher than WT JMJD1C (Fig. 7k, left).
Expression of oxidative genes, such as Acox1, was not affected,
revealing its specificity for lipogenic genes. We next examined the
effects of JMJD1C mutants in mice during fasting. WT mice,
along with JMDJ1C-LKO mice injected with GFP or Ad-JMJD1C
maintained low mRNA levels of lipogenic genes, whereas
JMJD1C-LKO mice injected with Ad-JMJD1C (T505D) had
2–3-fold higher mRNA levels of lipogenic genes even during
fasting when lipogenic genes were suppressed (Fig. 7, bottom
right), evidence of the critical function of T505 phosphorylation
for lipogenic gene activation. Overall, we conclude that mTOR
catalyzed JMJD1C T505 phosphorylation mediates activation of
lipogenic gene transcription upon insulin/feeding.
Discussion
Coordinate transcriptional regulation of lipogenic genes is one
the most exquisitely regulated processes in mammalian metabo-
lism. We previously reported the critical role of USF-1, which is
phosphorylated via a specific insulin signaling pathway involving
DNA-PK to recruit other factors, including P/CAF, and BAF60c,
to various lipogenic genes for transcriptional activation6,7.
However, these factors require accessible chromatin landscape
from proper histone modifications. We now determine that
JMJD1C is recruited by USF-1 to various lipogenic genes for
H3K9 demethylation to enhance chromatin accessibility in the
fed state. Moreover, we demonstrate that this is via mTORC
phosphorylation of JMJD1C at T505 to allow direct interaction
with USF-1 and via an increase in intracellular αKG levels, upon
feeding/insulin.
Histone modification, a major mode of epigenetic regulation, is
influenced by nutrients to alter chromatin accessibility12,16. One
Fig. 7 JMJD1C is phosphorylated at T505 by mTOR in response to insulin/feeding. a JMJD1C demethylase activity in HepG2 cells with or without insulin
treatment, n= 4 wells of cells per group (left) and in livers from fasted and fed mice, n= 3 per group (right). b Immunoblotting with phospho-serine
(p-Ser) and threonine (p-Thr) antibodies using lysates from HepG2 cells with or without Insulin treatment (left). Phosphorylated peptides detected by
mass spec analysis (right). c Diagram for phosphorylation sites detected by mass spec analysis (top). FAS promoter activity in HEK293 that were
transfected with JMJD1C serine or threonine mutants, n= 6 wells of cells per group (bottom). d IB with JMJD1C phospo-T505-specific antibody. JMJD1C
T505 phosphorylation in HepG2 cells upon insulin treatment (top) in livers of mice upon feeding (bottom). e Purified GST-JMJD1C from overexpression in
E.coli was incubated with mTOR complex with or without ATP. Immunoblotting with anti-phospho-threonine antibody after SDS-PAGE separation (left). IB
with phospho-T505 antibody after co-transfection with JMJD1C WT or T505A mutant with mTOR complex, after IP with JMJD1C antibody (right).
f Treatment of mice with vehicle or rapamycin (10mg/kg), IB for phosphor-T505 and total Jmjd1c (left) and lipogenic gene mRNA levels in liver (right) n=
5. g Knockdown of Raptor in mouse liver, IB for phospho-T505, total Jmjd1c, Raptor, and Gapdh (left), and mRNA levels of lipogenic genes (right), n= 5.
h IB following co-IP of JMJD1C mutants with USF-1. i IB of Usf-1 following IP of Jmjd1c (top) and IB of Jmjd1c following IP of Usf-1 (bottom) from mouse
fasted and refed mouse liver. j ChIP–qPCR using FAS promoter luc construct to assess enrichment of JMJD1C mutants upon insulin treatment, n= 4 wells
of cells per group. k IB for Jmjd1c from livers of WT and JMJD1C-LKO mice injected with designated virus (top). RT-qPCR for lipogenic gene mRNA levels in
livers from WT and JMJD1C-LKO mice 10 days after tail-vein injection of JMJD1C or its mutant T505D adenovirus in refed (left) and fasted (right)
conditions, n= 5 per group. l Representative schematic of insulin signaling pathways converging on USF-1 for recruitment of JMJD1C and other co-factors
for the activation of transcription of lipogenic genes. Solid lines show established pathways, dashed lines show undefined pathways. a–k Data are expressed
as means ± SEM. *denotes p < 0.05, determined by two-tailed t-test. Source data are provided as a source data file.
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such histone modification is H3K9 methylation14,31. H3K9me2
and H3K9me3 are reported to be enriched in the TSS of silenced
genes and are correlated with transcriptional repression.
H3K9me1 could also be found in the promoter regions of active
or silent genes, although its role remains controversial32–36.
Numerous H3K9 demethylases have been identified and most of
them belong to the Jumonji family with 30 members. Here, we
report that JMJD1C, one of Jumonji HDM family members,
functions specifically for lipogenic gene activation in response
to feeding/insulin. By direct interaction, USF-1 recruits JMJD1C
to lipogenic promoters for H3K9me2 demethylation to alter
chromatin accessibility in response to insulin/feeding. Our
ATAC-seq clearly show that demethylation of H3K9me2 coin-
cides with increased chromatin accessibility. Moreover, depletion
of JMJD1C results in higher H3K9me2 and H3K9me3 at lipo-
genic promoters in the livers of JMJD1C-LKO, preventing
the chromatin remodeling necessary to activate transcription.
RNA-seq also confirmed downregulation of lipogenic genes in the
livers of JMJD1C-LKO mice. However, gluconeogenic genes
known to be suppressed in fed and activated in fasted state37 were
not affected by JMJD1C ablation, suggesting involvement of a
distinct H3K9 demethylase, but not JMJD1C, for regulation of
gluconeogenic genes.
Lower hepatic α-ketoglutarate level after an overnight fast and
higher α-ketoglutarate level in fed mice are consistent with a
previous report of decreased hepatic αKG at 12–24 h fast,
although this decrease appeared to recover after a longer fast-
ing38. Untargeted metabolomic studies in rats also showed lower
αKG levels during fasting39. Our observation of insulin/feeding-
induced increase in αKG level is congruent with the concept that
αKG increased upon feeding/insulin treatment serves as a co-
substrate for JMJD1C for demethylation of H3K9 for lipogenic
gene activation. While JMJD1C demethylates H3K9me2 for
transcriptional activation, there are other members of the JmjC
family, such as KDM5/JARID, that demethylate H3K4 for tran-
scriptional repression40. Therefore, while αKG is required for
JmjC demethylases, it is not the determining factor for specific
JmjC members. Demethylase activity of JMJD1C in vitro clearly
show that even in the presence of an excess of αKG, JMJD1C
purified from insulin-treated or refed liver, had greater activity
than JMJD1C purified from serum starved/fasted liver. Regard-
less, αKG level was shown to be higher in hepatosteatosis and, in
fact, was identified as a metabolic marker for hepatosteatosis41.
In our present study, we provide a functional and mechanistic
link between feeding/insulin-triggered mTOR signaling and
downstream epigenetic modification involving JMJD1C. We
show that changes in H3K9 methylation status due to mTOR-
mediated phosphorylation of JMJD1C at T505 is a critical epi-
genetic event, leading to chromatin changes to allow lipogenesis.
mTOR signaling has previously been implicated in lipogenic gene
activation by inducing SREBP-1c42. mTOR activity is thought to
increase cleavage of SREBP-1c for nuclear accumulation for
lipogenic gene transcription, however, the underlying mechanism
is not clear43,44. Our finding of phosphorylation of JMJD1C at
T505 by mTOR reveals an important target and demonstrates the
molecular mechanism for mTOR in lipogenic gene activation. We
show that mTOR phosphorylates JMJD1C at T505, which is
required for its direct interaction with USF-1 to be recruited to
lipogenic promoters to allow chromatin accessibility. In response
to insulin, USF-1 is phosphorylated by DNA-PK, whereas
BAF60c is phosphorylated by atypical PKC to be recruited to the
lipogenic promoters10,32. Thus, the three branches of insulin
signaling pathway need to converge and the triad of DNA-PK-
aPKC-mTOR underlies signaling for transcriptional activation of
lipogenesis in response to insulin/feeding.
Nutrition is the principal contributory factor affecting hepa-
tosteatosis and carbohydrate in the diet is the major source of
hepatic FA production in steatotic subjects45. Thus, lipogenesis is
a major contributing component in development of hepatostea-
tosis. Our present study demonstrates that depletion of JMJD1C
lowered rates of lipogenesis and prevented accumulation of TG in
liver thus protecting mice from development of hepatosteatosis.
Interestingly, this lowered lipogenesis was met with greater
accumulation of hepatic glycogen, as carbohydrate metabolites
were funneled into glycogen synthesis instead. JMJD1C may
provide therapeutic targets for preventing and/or controlling the
development of hepatosteatosis.
The interrelationship between IR and the abnormalities of
hepatic lipid homeostasis is not clear46, since IR also accompanies
abnormalities in other insulin-sensitive tissues, such as adipose
and muscle. In this regard, ChREBP knockdown in the liver was
shown to improve hepatosteatosis, as well as insulin sensitivity, in
obese ob/ob mice47. In the present study, we show that liver-
specific ablation of JMJD1C protects mice from hepatosteatosis
and IR arising from high-CHO feeding, in the absence of
increased adiposity. In population studies, a strong correlation
has been reported between hepatosteatosis and IR independent of
body mass index48,49. Our study suggests that preventing hepa-
tosteatosis can improve IR in the absence of obesity. This implies
that hepatosteatosis may lead to IR. Several GWAS studies
identified JMJD1C as a prime candidate associated with plasma
TG levels and VLDL size, as well as type 2 diabetes17–21. Inter-
estingly, the loci identified (Chr10:63214669, Chr10:63214701,
Chr10:63214700) corresponded to SNP close to T505. In con-
clusion, as we identify the USF-1−JMJD1C−H3K9me2 signaling
axis, targeting JMJD1C phosphorylation by mTOR could provide
a therapeutic strategy against hepatosteatosis and IR through
perturbation of crucial lipogenic insulin signaling cascade.
Methods
Animals. Animal experiments were conducted in compliance with all relevant
ethical regulations for animal testing and research, and were approved by the
University of California Berkeley Animal Care and Use Committee. Generation
of Liver-specific JMJD1C knockout mice (JMJD1C-LKO): engineered JMJD1C
mice were obtained from EMMA. These mice were bred with FLP deleter ROSA-
FLPe mice (Jackson) to remove the Neo cassette, and then bred with albumin
promoter driven Cre mice (Alb-Cre) (Jackson) to generate mice of liver-specific
JMJD1C deletion. JMJD1C-LKO mice and their C57bl/6j WT littermates were
used at 12 weeks of age unless specified otherwise. For fasting/feeding experi-
ments, mice were fasted overnight and then fed a high CHO, fat-free diet for
8–16 h. High-CHO diet (70 kcal% carbohydrate), high-fat diet (45 kcal% fat),
and high-cholesterol diet (1.5% added cholesterol) were purchased from
Research Diets.
Antibodies, cell culture, plasmid transfection. Rabbit polyclonal-specific phos-
pho-T505 of JMJD1C antibodies were raised against the peptide corresponding to
aa 496–512 of JMJD1C (KEKFVSRPPTPKCVIDI) phosphorylated at T505
(P-T505) (Genemed). The specific antibody was affinity-purified using the
phospho-peptide before use (diluted 1:500). The following commercial antibodies
were used: JMJD1C (sc-101073, 1:500), GAPDH (sc-32233, 1:2000), USF-1 (sc-229,
1:1000), HDAC1 (sc-7872, 1:1000), Fatty acid synthase (sc-55580, 1:1000), and
SREBP-1c (sc-366, 1:1000) from SCBT. FLAG (147935, 1:1000), HA (C29F4,
1:1000), and Raptor (24C12, 1:750) from CST. phospho-Threonine (05-1923,
1:200), phosphor-Serine (Ab1603, 1:200), and normal IgG (PP64B, 2 µg/µg of
chromatin) from EMD Millipore. GFP (ab1218, 1:1000), Total H3 (ab1791, 2 µg/µg
of chromatin), H3K9me1 (ab9045, 2 µg/µg of chromatin), H3K9me2 (ab176882,
2 µg/µg of chromatin), H3K9me3 (ab8898, 2 µg/µg of chromatin), and H3K4me3
(ab8580, 2 µg/µg of chromatin) from Abcam. Full-length human JMJD1C plasmid
was obtained from OriGene.
HepG2 and 293FT cells were obtained from ATCC. Cells were grown in
Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine
serum and 100 units/mL of penicillin and streptomycin. HepG2 cells were
maintained in serum-free media overnight prior to treatment with 100 nM insulin
for 30 min. HEK293FT cells in DMEM were supplemented with 10% fetal bovine
serum and 100 units/mL penicillin, streptomycin, and neomycin, and 293F cells in
293 Freestyle media were transfected with plasmids using Lipofectamine 2000
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(Invitrogen). Adenovirus containing JMJD1C, sh-JMJD1C, and JMJD1C mutants
(T505A and T505D) were generated by Vector Biolabs and were used for infecting
HepG2 cells or for tail-vein injection into mice.
Mass spectrometry analysis. To identify USF-1 interacting proteins we employed
tandem affinity purification (TAP), using TAP-tagged USF-1 as bait, and incubated
USF-1 with liver nuclear extracts prior to submission for mass spectrometry
analysis. Site-specific phosphorylation of JMJD1C was detected by enzymatically
digesting HA-purified JMJD1C from HepG2 nuclear extracts and subjecting
digested peptides to two-dimensional “MudPIT” run (cation exchange/reversed-
phase liquid chromatography–tandem MS) using a Thermo LTQ XL mass spec-
trometer. DTASelect program was used to interpret the mass spectra.
JMJD1C activity and α-ketoglutarate levels. JMJD1C was overexpressed in
HepG2 cells by JMJD1C-HA adenovirus. After treatment with 100 nM insulin for
30 min, JMJD1C was purified from cell lysates of HepG2 cells and purified using
HA beads. In vitro demethylation assay was performed using ELISA kits containing
methylated H3K9 (Active Motif and Epigentek), according to the manufacturer’s
instructions. To determine substrate specificity, we incubated purified JMJD1C
with individual substrate, H3K9me3, H3K9me2, or H3K9me1 for 60 min. After
primary and secondary antibody treatments, samples were incubated with the
developing solution before measuring absorbance at 450 nm on a spectro-
photometer. Remaining substrate levels were calculated using the standard curve.
Total JMJD1C demethylase activity was measured using H3K9 Specific
demethylase kit (Epigentek, P-3077-48). Briefly, JMJD1C was purified from
JMJD1C-HA overexpressing HepG2 cells with or without 100 nM insulin
treatment. JMJD1C was incubated with substrate and co-factor in assay buffer for
60 min. After washing, fluorescence developing solution was added and
fluorescence intensity was measured by excitation at 530 nm and emission at
590 nm. For hepatic JMJD1C activity, nuclear proteins were extracted from livers
of mice that were fasted or fed. JMJD1C was purified by using JMJD1C antibody
and protein A/G Plus agarose (Thermo-Fisher), before subjecting them to
demethylation assay.
α-ketoglutarate levels were measured by using an α-ketoglutarate assay kit
(Abcam, ab83431). Briefly lysates of cells or tissues were incubated with the enzyme
reaction mixture for 30 min at 37 °C for transamination of α-ketoglutarate with the
generation of pyruvate that was utilized to convert a probe to a color, which were
read by spectrophotometer at 570 nm. α-ketoglutarate concentration was calculated
by using a standard curve.
ChIP–qPCR and ChIP-seq. ChIP was performed using ChIP kit (Cell signaling,
57976s). Briefly, HepG2 cells with or without insulin treatment and livers from
fasted or fed mice were fixed with disuccinimidyl glutarate (DSG) at 2 mM con-
centration in PBS for 45 min at room temperature before cross-linking with 1%
formaldehyde in PBS for 10 min. The reaction was stopped by incubating with
125 mM glycine for 10 min. Cells or tissues were rinsed with ice-cold phosphate-
buffered saline (PBS) for three times, and lysed in IP lysis buffer containing
500 mM HEPES-KOH, pH 8, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 0.5%
NP-40, 0.25% Triton X-100, 10% glycerol, and protease inhibitors for 10 min at
4 °C. Nuclei were collected by centrifugation at 600 × g for 5 min at 4 °C. Nuclei
were released by douncing on ice and collected by centrifugation. Nuclei were then
lysed in nuclei lysis buffer containing 50 mM Tris, pH 8.0, 1% SDS 10 mM EDTA
supplemented with protease inhibitors, and sonicated three times by 20 s burst,
each followed by 1 min cooling on ice. Chromatin samples were diluted 1:10 with
the dilution buffer containing 16.7 mM Tris pH 8.1, 0.01% SDS 1.1 % Triton X-100
1.2 mM EDTA, 1.67 mM NaCl, and proteinase inhibitor cocktail. Soluble chro-
matin was quantified by absorbance at 260 nm, and equivalent amounts of input
DNA were immunoprecipitated using 10 μg of indicated antibodies or normal
mouse IgG (Santa Cruz) and protein A/G magnetic beads (Thermo-Fisher). After
the beads were washed and cross-linking reversed, DNA fragments were purified
using QIAquick DNA purification kit (Qiagen). The promoter occupancy for FAS
and other indicated genes was confirmed by qPCR. The fold enrichment values
were normalized to input.
For ChIP-seq, we used two mice per condition and processed chromatin
separately, thus each sample analyzed was a separate biological replicate. Library
preparation and ChIP-seq were performed with eluted DNA using an Illumina
Hiseq4000 sequencer by the QB3 Berkeley Genomics Lab (Berkeley, CA). Partek
Flow Genomics Suite was used to analyze sequencing data. Reads were aligned to
mm10 genome assembly using Bowtie2 and only reads aligned to a unique genome
location were reported. The aligned reads were then subjected to peak calling using
MACS2 with a q-value cutoff of 0.05. Reads with 2.5-fold enrichment compared to
the input sample, were considered as peaks. Peaks were annotated by overlapping
to RefSeq mRNA database and visualized using UCSC genome browser. Gene set
enrichment and pathway analysis was used to highlight biological processes with
the highest q-values among those identified.
ATAC-seq. For ATAC-seq, we used two mice per condition and processed nuclei
extracted from liver separately, thus each sample analyzed was a separate biological
replicate. ATAC-seq was performed using Nextera DNA library Preparation kit
(Illumina, 15028212) according to Chen et al. 50. In all, 5 × 104 nuclei from cells or
tissues were collected in lysis buffer containing 10 mM Tris pH 7.4, 10 mM NaCl,
3 mM MgCl2, and 1% NP-40, and spun at 500 × g at 4 °C for 10 min. The pellets
were resuspended in the transposase reaction mixture containing 25 μL 2 × Tag-
mentation buffer, 2.5 μL transposase, and 22.5 μL nuclease-free water, and incu-
bated at 37 °C for 30 min. The samples were purified using MinElute PCR
Purification kit (Qiagen, 28006) and amplification was performed in 1 × next PCR
master mix (NEB, M0541S) and 1.25 μM of custom Nextera PCR primers 1 and 2
with the following PCR conditions: 72 °C for 5 min; 98 °C for 30 s; and thermo-
cycling at 98 °C for 10 s, 63 °C for 30 s, and 72 °C for 1 min. Samples were amplified
for five cycles and 5 μL of the PCR reaction was used to determine the required
cycles of amplification by qPCR. The remaining 45 μL reaction was amplified with
the determined cycles and purified with MinElute PCR Purification kit (Qiagen,
28006) yielding a final library concentration of ~30 nM in 20 μL. Libraries were
subjected to pair-end 50 bp sequencing on HiSeq4000 with 4–6 indexed libraries
per lane. Partek Flow Genomics Suite was used to analyze sequencing data. Reads
were aligned to mm10 genome assembly using BWA-backtrack. MACS2 in ATAC
mode was then used to identify peaks from the aligned reads with a q-value cutoff
of 0.05 and fold enrichment cutoff of 2.0. Quantify regions tool was used to
quantify the peaks identified by MACS2 from each sample to generate a union set
of regions. Regions were then annotated to RefSeq mRNA database and analysis of
variance (ANOVA) was performed to determine significant peak differences
between groups. UCSC genome browser was used to visualize peaks. Gene set
enrichment and pathway analysis was used to highlight biological processes with
the highest q-values among those identified.
Glycogen staining and measurement. Periodic acid–Schiff (PAS) staining kit for
glycogen was purchased from Sigma. Briefly, paraffin-embedded liver and muscle
sections were deparaffinized and hydrated with water. Oxidized in 0.5% periodic
acid solution for 5 min and rinsed in distilled water. Sections were placed in Schiff
reagent for 15 min, washed in lukewarm tap water for 5 min followed by Mayer’s
hematoxylin counterstaining for 1 min, washed in tap water for 5 min and dehy-
drated, and coverslipped using a synthetic mounting medium. Glycogen levels in
liver and muscles of the mice were using glycogen assay kit (sigma). Briefly, 10 mg
of tissues were homogenized in 100 μl water and boiled for 5 min. Homogenates
were clarified by centrifugation at 13,000 × g for 5 min. Supernatant was used for
the assay. Samples were diluted to final volume of 50 μL with hydrolysis buffer.
Samples together with standards were added with 2 μL of hydrolysis enzyme mix,
and incubated at room temperature for 30 min. Then developed by adding 50 μL
master reaction mix containing development enzyme mix, buffer, and peroxidase
substrate. For colorimetric assay, the absorbance was measured at 570 nm. Con-
centration of glycogen were calculated by using the standard curve.
In vitro phosphorylation. mTOR complex components, Myc-mTOR (Addgene,
1861), HA-Raptor (Addgene, 8513), and Flag-Rheb (Addgene, 19996), were
transfected individually into HEK293 cells grown in 100 mm dishes (2 × 106 cells),
and each component was purified from cell lysates using Myc, HA, and Flag
antibodies. GST-JMJD1C purified after expressing it in E. coli was incubated with
mTOR complex (1:1:1 ratio of total 300 ng in 15 μL) in the kinase buffer containing
50 mM HEPES, pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 1 mM DTT with or without
500 μM ATP at 25 °C for 1 h and the reaction was terminated by adding 20 μL 2 ×
SDS sample buffer. Phosphorylation reaction mixture containing 0.5 μg of protein
was separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and JMJD1C phosphorylation was detected with pan-phospho-serine and
pan-phospho-threonine antibodies or phospho-specific anti-peptide antibody that
we have raised as indicated above.
Immunoprecipitation, GST pull-down, and luciferase reporter assays. For
immunoprecipitation, nuclear extracts were incubated with the specific antibodies
overnight at 4 °C followed by protein G agarose beads (Santa Cruz) and the
immunoprecipitates were separated by SDS-PAGE. Proteins were transferred onto
nitrocellulose membranes (BioRad) for immunoblotting. For GST pull-down,
bacterially expressed GST-USF-1 fusion proteins on glutathione-agarose beads
(Santa Cruz) were incubated with 35S labeled in vitro transcribed and translated
proteins. The complex formed was separated by SDS-PAGE before auto-
radiography. The 293FT cells were transfected with-444-FAS-Luc along with var-
ious expression constructs using Lipofectamine 2000 (Invitrogen) and luciferase
assays were performed using Dual-Luc reagent (Promega).
Quantitative reverse transcription PCR (RT-qPCR). One microgram of total
RNA isolated using Trizol reagent (Gibco-BRL) were reverse transcribed and the
resultant cDNAs were amplified by qPCR using 7500 Fast Real-time PCR system
(ABI). The relative mRNA levels were quantified using GAPDH as control. Primer
sets for FAS, mGPAT, ACC, SCD1, and SREBP-1c, were from Elimbio. Statistical
analysis of the qPCR was obtained using the TMCt method.
Preparation of Nascent RNA. Livers from three mice were homogenized in five
volumes of buffer containing 0.32M sucrose, 3 mM MgCl2, 5 mM Hepes (pH 6.9),
and 0.5 mM 8-mercaptoethanol. Nuclei collected by centrifugation were washed
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once by centrifugation through a 2.1 M sucrose cushion at 20,000 rpm for 60 min
in a Beckman SW 28 rotor. The nuclei were stored in liquid nitrogen in 50 mM Tris
(pH 7.9), 5 mM MgCl2, 0.5 mM 8-mercaptoethanol, and 40% glycerol. Nuclei were
treated with DNase (Roche) and RNA were purified using RNeasy kit (Qiagen).
Measurement of rate of de novo lipogenesis. Fatty acids synthesized during a
24-h 2H2O body water-labeling period were measured51. Mass Isotopomer Dis-
tribution Analysis (MIDA) was performed. Fractional DNL contribution was cal-
culated as previously described by ƒDNL= EM1FA/A52.
Statistical analysis. Statistical comparisons were made using a two-tailed
unpaired t-test using GraphPad Prism 8 software (GraphPad Software Inc., La
Jolla, CA, USA). For genome-wide analyses, we employed Partek Genomics Suite
(Partek Inc., St. Louis, Missouri, USA) using ANOVA for ATAC- and ChIP-seq
comparisons, and DESeq2 for RNA-seq differential expression comparisons, and
subsequently used Gene set enrichment tool for gene ontology to identify the
significantly affected pathways presented in Fig. 5.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The genomic and transcriptomic datasets generated and analyzed during the current
study are available in the GEO repository under accession number: GSE142815. The
proteomic datasets generated and analyzed during the current study are available in the
MassIVE repository under accession number MSV000084745.
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